Therapeutic nuclear medicine in pediatric malignancy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 4, 2010, Pages 411-428

  Schmidt, M ^b   Baum, R P ^a   Simon, T ^b   Howman Giles, R ^c  

^a Center for PET   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Child; Neoplasms; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; AMINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETIDRONIC ACID RE 186; ETOPOSIDE; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; MEMBRANE RECEPTOR; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; SAMARIUM LEXIDRONAM; SOMATOSTATIN RECEPTOR; STRONTIUM 89; THYROID HORMONE; TOPOTECAN; UNCLASSIFIED DRUG;

ADRENAL DISEASE; AMENORRHEA; AMINE TRANSPORT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CHILDHOOD CANCER; DIAGNOSTIC IMAGING; DOSE RESPONSE; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG TOLERABILITY; FATIGUE; HEART DISEASE; HUMAN; ISOTOPE LABELING; LEUKEMIA; LIVER DYSFUNCTION; LUNG METASTASIS; MONOTHERAPY; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NUCLEAR MEDICINE; OSTEOSARCOMA; PAROTITIS; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; RADIOISOTOPE THERAPY; SIALOADENITIS; THROMBOCYTOPENIA; THYROID CANCER; THYROID DISEASE; THYROIDECTOMY; WHOLE BODY SCINTISCANNING; XEROSTOMIA;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; NEOPLASMS; NEUROBLASTOMA; NEUROENDOCRINE TUMORS; OSTEOSARCOMA; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RECEPTORS, SOMATOSTATIN; THYROID NEOPLASMS;

EID: 78650640905     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (104)

1. Wright JH. Neurocytoma or neuroblastoma. A kind of tumor not generally recognized. J Exp Med 1910;12:556-61.
2. Kaatsch P, Spix C. Annual report 2005. German Childhood Cancer Registry, Mainz 2006; p. 56.
3. Goodman M, Gurney J, Smith M, Olshan A. Sympathetic nervous system tumors. In: Ries L, Smith M, Gurney J, editors. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Institutes of Health: National Cancer Institute, SEER Program; 1999. p. 65-7.
4. Lessig MK. The role of 131I-MIBG in high-risk neuroblastoma treatment. J Pediatr Oncol Nurs 2009;26:208-16.
5. Berthold F, Hero B, Kremens B, Kremens B, Handgretinger R, Henze G et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 2003;197:11-7.
6. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med 1979;20:155-8.
7. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53.
8. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh DD, Mangner TJ et al. Imaging the primate adrenal medulla with [1231] and [1311] meta- iodobenzylguanidine: concise communication. J Nucl Med 1981;22:358-64.
9. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med 1979;20:155-8.
10. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol 2008;35 (Suppl 1):S35-48
11. Howman-Giles R, Shaw PJ, Uren RF, Chung DK. Neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 2007;37: 286-302.
12. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-18.
13. Vaidyanathan G, Affleck DJ, Zalutsky MR. No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. Appl Radiat Iso 2005;62:435-40.
14. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med Mol Imaging 2008;52:351-68.
15. McCluskey AG, Boyd M, Pimlott SL, Babich JW, Gaze MN, Mairs RJ. Experimental treatment of neuroblastoma using [13H]meta-iodobenzylguanidine and topotecan in combination. BrJ Radiol 2008;81:S28-35.
16. McCluskey AG, Boyd M, Ross SC, Cosimo E, Clark AM, Angerson WJ et al. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter. Clin Cancer Res 2005;11:7929-37.
17. Mairs RJ, Fullerton NE, Cosimo E, Boyd M. Gene manipulation to enhance MIBG-targeted radionuclide therapy. Nucl Med Biol 2005;32:749-53.
18. Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131I]iodibenzylguanidine. Appl Radiat Isot 1993;44: 621-8.
19. Mairs RJ, Cunningham SH, Russell J, Armour A, Owens J, McKellar K, Gaze MN. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation. J Nucl Med. 1995;36:1088-95.
20. Mairs RJ, Russell J, Cunningham S, O'Donoghue JA, Gaze MN, Owens J et al. Enhanced rumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 1995;31:576-81
21. Cornelissen J, Van Kuilenburg AB, Voute PA, Van Gennip AH. MIBG causes oxidative stress and up-regulation of anti-oxidant enzymes in the human neuroblastoma cell line SK-N-BE(2c). Int J Cancer 1997;72:486-90.
22. Cornelissen J, Wanders RJ, Van den Bogen C, Van Kuilenburg AB, Elzinga L, Voute PA et al. Metaiodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c). Eur J Cancer 1995;31A:582-6.
23. Armour A, Cunningham SH, Gaze MN, Wheldon TE, Mairs RJ. The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. BrJ Cancer 1997;75:470-6.
24. Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE. Noradrenaline transporter gene transfer for radiation cell kill by 1311 meta- iodobenzylguanidine. Gene Ther 1999;6:1147-52.
25. Boyd M, Mairs RJ, Cunningham SH, Mairs SC, McCluskey A, Livingstone A, et al. A gene therapy/targeted radiotherapy strategy for radiation cell kill by. J Gene Med 2001;3:165-72.
26. Mairs RJ, Cunningham SH, Boyd M, Carlin S. Applications of gene transfer to targeted radiotherapy. Curr Pharm Des 2000; 6:1419-32.
27. Cunningham S, Boyd M, Brown MM, Carlin S, McCluskey A, Livingstone A et al. A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Med Pediatr Oncol 2000; 35:708-11.
28. Hutchinson RJ, Sisson JC, Miser JS, Zasadny KR, Normolle DP, Shulkin BL et al. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma. J Nucl Biol Med 1991;35:237-40.
29. Hutchinson RJ, Sisson JC, Shapiro B, Miser JS, Normole D, Shulkin BL et al. I-131-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 1992;15:226-32.
30. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meiler S, Kemshead JT et al. Phase I/F;II study ofiodine 131 metaiodobenzylguanidine in chemoresistant neuroblastomas United Kingdom Children's Cancer Study Group investigation. Journal of Clinical Oncology 1992;10:1889-96.
31. Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A et al. Phase I dose escalation of 1311-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998;16:229-36.
32. Matthay KK, Tan JC, Villabianca JG, Yanik GA, Veatch J, Franc B etal. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stemcell transplantation in refractory neuroblastomas new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24:500-6
33. Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H et al. Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastomas new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009;27:1020-5
34. Lumbroso J, Hartmann O, Schlumberger M. Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastomas phase II study in 26 patients. "Societe Francaise d'Oncologie Pediatrique" and Nuclear Medicine Co-investigators. J Nucl Biol Med 1991;35:220-3.
35. Hoefnagel CA, Voute PA, De Kraker J, Valdes Olmos RA. [1311] metaiodobenzylguanidine therapyafter conventional therapy for neuroblastoma. J Nucl Biol Med 1991;35:202-6.
36. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25: 1054-60.
37. Corbett R, Pinkerton R, Tait D, Meiler S. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 1991;35:228-31.
38. Gaze MN, Wheldon TE, O'Donoghue JA, Hilditch TE, McNee SG, Simpson E et al. Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue:feasibility study of a new strategy for advanced neuroblastoma [see comments]. Eur J Cancer 1995;31A:252-6.
39. Klingebiel T, Bader P, Bares R, Beck J, Hero B, Jurgens H et al. Treatment of neuroblastoma stage 4 with 1311-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998;34:1398-402.
40. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stemcell support for the treatment of neuroblastoma. J Clin Oncol 2002;20:2142-9.
41. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F et al. Is there a benefit of 1311-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006;45:145-51.
42. Klingebiel T, Berthold F, Treuner J, Schwabe D, Fischer M, Feine U et al. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma:results of the German Neuroblastoma Trial. Med Pediatr Oncol 1991;19:84-8.
43. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2010 - in press -
44. De Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008;44:551-6.
45. Sudbrock F, Eschner W, Schmidt M, Simon T, Hero B, Schicha H. Dosimetry for therapeutic treatment of neuroblastoma by 1311-mIBG. Nuklearmedizin 2006;45:254-61.
46. Buckley SE, Chittenden SJ, Saran FH, Meiler ST, Flux GD. Wholebody dosimetry for individualized treatment planning of 1311-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009; 50:1518-24
47. Buckley SE, Saran FH, Gaze MN, Chittenden S, Partridge M, Lancaster D, et al. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:preliminary results. Cancer Biother Radiopharm 2007;22: 105-12.
48. Modak S, Pandit-Taskar N, Kushner BH, Kramer K, Smith-Jones P, Larson S, Cheung NK. Transient sialoadenitiss complication of 131I-metaiodobenzylguanidine therapy. Pediatr Blood Cancer 2008;50:1271-3.
49. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T.High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002;94:2081-9.
50. van Santen HM, de Kraker J, van Eck BL, de Vijlder JJ, Vulsma T. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer 2003;98:389-96.
51. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK. Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 2003;25:543-7.
52. Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR et al. Second malignancies in children with neuroblastoma after combined treatment with 1311-metaiodobenzylguanidine. Cancer 2003;97:1332-8.
53. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77-9.
54. Ruffini V, Calcagni ML, Baum RP. Imaging of Neuroendocrine Tumors. Semin Nucl Med 2006;36:228-47.
55. Baum RP, Prasad V. PET and PET/CT imaging of neuroendocrine tumors. In:Principles and practice of PET and PET/CT. 2nd edition 2009. Philadelphia: Wolter Kluwer, Lippincott, Williams & Wilkins; p. 411-37.
56. Spunt SL, Pratt CB, Rao BN, Pritchard M, JenkinsJJ, Hill DA et al. Childhood carcinoid tumorsThe St Jude Children's Research Hospital experience. J Pediatr Surg 2000;35:1282-6.
57. Broaddus RR, Herzog CE, Hicks MJ. Neuroendocrine tumors (carcinoid and neuroendocrine carcinoma) presenting at extra-appendiceal sites in childhood and adolescence. Arch Pathol Lab Med 2003;127:1200-3.
58. Khanna G, Bushnell D, O'Dorisio MS. Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors. Oncologist 2008;13:382-9.
59. Pashankar FD, O'Dorisio MS, Menda Y. MIBG and somatostatin receptor analogs in children:Current concepts on diagnostic and therapeutic use. J Nucl Med 2005;46(suppl 1):55S-61S.
60. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med 1998;25:675-86.
61. Beutler D, Avoledo P, Reubi JC, Mäcke HR, Müller-Brand J, Merlo A et al. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal yttrium-90-labeled DOTA0-D-Phel-Tyr3-octreotide radiopeptide brachytherapy. Cancer 2005;103: 869-73.
62. Baum RP, Prasad V. Monitoring Treatment. In: Cook GJR, Maisey MN, Britton KE, Chengazi V, editors. Clinical Nuclear Medicine. 4th edition. New York: Hodder Arnold; 2006. p. 57-78.
63. Charron M, BrownM, Rowland P, Miro J. Pain palliation with strontium-89 in children with metastatic disease. Med Pediatr Oncol 1996;26:393-6.
64. Gompakis N, Triantafyllou P, Sidi B, Koliouskas ED, Salem N, Pistevou K. Strontium-89 for palliation of bone pain. Med Pediatr Oncol 2003;40:136.
65. Sawyer EJ, Cassoni AM, Waddington W, Bomanji JB, Briggs TWR. Rhenium-186 HEDP as a boost to external irradiation in osteosarcoma. Brit J Radiol 1999;72:1225-9.
66. Anderson P, Nunez R. Samarium lexidronam (153Sm-EDTMP):skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 2007;7:1517-27.
67. Welsh JS, Thurman SA, Borzillary S, Schwartz CL, Howard SP. Sm-153 EDTMP for recurrent metastatic osteosarcoma. Clin Adv Hematol Oncol 2003;1:181-3.
68. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate:low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:189-96.
69. Claude L, Rousmans S, Carrie C, Breteau N, Dijoud F, Gentet JC et al. Institut National du Cancer;Fédéation nationale des centres de lutte contre le cancer (FNCLCC);Standards, Options et Recommendations;Ligue nationale contre le cancer; SFCE; Fédéation hospitalière de France;FNCHRU;Fédéation française de cancérologie. Standards and Options for the use of radiation therapy in the management of patients with osteosarcoma. Update 2004]. Bull Cancer 2005;92:891-906.
70. Claude L, Rousmans S, Carrie C, Breteau N, Dijoud F, Gentet JC et al. Institut National du Cancer;Fédéation nationale des centres de lutte contre le cancer (FNCLCC);Standards, Options et Recommendations;Ligue nationale contre le cancer; SFCE; Fédéation hospitalière de France;FNCHRU;Fédéation française de cancérologie. Standards and Options for the use of radiation therapy in the management of patients with osteosarcoma. Update 2004L Bull Cancer 2005,92:891-906.
71. Franzius C, Bielack S, Flege S, EckardtJ, Sciuk J, Jürgens H et al. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 2001;40:215-20.
72. Franzius C, Bielack S, Sciuk J, Vollet B, Jürgens H, Schober O. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin 1999;38:337-40.
73. Franzius C, Schuck A, Bielack SS. High-dose samarium-153 ethylene diamine tetramethylene phosphonate:low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20:1953-4.
74. Essman SC, Lewis MR, Miller WH. Intraorgan biodistribution and dosimetry of 153Sm-ethylenediaminetetramethylene phosphonate in juvenile rabbit tibia:implications for targeted radiotherapy of osteosarcoma. J Nucl Med 2005;46:2076-82.
75. Essman SC, Lewis MR, Fox DB Effects of increasing doses of samarium-153-ethylenediaminetetramethylene phosphonate on axial and appendicular skeletal growth in juvenile rabbits. Nucl Med Biol 2008;35:219-25.
76. Thompson, GB, Hay ID. Current Strategies for Surgical management and Adjuvant Treatment of Childhood Papillary Thyroid Carcinoma. World J Surg 2004;28:1187-98.
77. Dinauer CA, Breuer C, Rivkees SA. Differentiated thyroid cancer in children:diagnosis and management. Curr Op Oncol 2008: 2059-65.
78. Dinauer C, Francis GL. Thyroid cancer in children. Endocrinol Metab Clin N Am 2007;36:779-806.
79. Parisi MT, Mankoff D. Differentiated pediatric thyroid cancer:correlates with adult disease, controversies in treatment. Semin Nucl Med 2007;37:340-56.
80. Jarzab B, Handkiewicz-Junak D, Wloch D. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatments qualitative review. Endocrine-Related Cancer 2005;12:773-803.
81. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin N Am 2007;36:807-22.
82. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L et al. Total Thyroidectomy and Adjuvant Radioiodine Treatment Independently Decrease Locoregional Recurrence Risk in Childhood and Adolescent Differentiated Thyroid Cancer. J Nucl Med 2007;48:879-88.
83. Middendorf M, Grunwald F. Update on recent developments in the therapy of differentiated thyroid cancer. Semin Nucl Med 2010;40:145-52.
84. Hogan AR, Zhuge Y, Perez E A, Koniaris LG, Lew JI, Sola JE. pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Research 2009;156:167-72.
85. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid 2002;12:683-702.
86. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009;19:1-48.
87. Savio R, Gosnell J, Palazzo FF, Sywak M, Agarwal G, Cowell C et al. The role of more extensive surgical approach in the initial multimodality managment of papillary thyroid ancer in children. J Pediatr Surg 2005;1696-700.
88. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Francis GL. Extensive surgery improves recurrence-free survival for children and young patients with class 1 papillary thyroid carcinoma. J Pediatr Surg 1999;1799-804.
89. Haverman JW, van Tol KM, Rouwé CW, Piers DA, Plukker JT. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol 2003;10:15-20
90. Sippel, Chen H. Controversies in the Surgical Management of newly Diagnosed and Recurrent/Residual Thyroid Cancer. Thyroid 2009;1373-80.
91. Dralle H, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Practice & Research Clinical Endocrinology and Metabolism 2008;22:971-87.
92. Gingalewski CA, Newman KD. Seminars:Controversies in the Management of Pediatric Thyroid Malignancy. J Sutg Oncol 2006; 94:748-52.
93. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S. Comprehensive Clinical Assessment of 740 Cases of Surgically Treated Thyroid Cancer in Children of Belarus. Ann Surg 2006;243:525-32.
94. Jonklass J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD et al. Outcomes of patients with differentiated thyroid cancer following initial therapy. Thyroid 2006;16:1299-342.
95. Ito Y, Jikuzono T, Higashiyama T, Asahi S, Tomoda C, Takamura Y et al. Clinical significance of lymph node metastais of thyroid papillary carcinoma located in one lobe. World J Surg 2006;30:1821-8.
96. Chow SM, Law SCK, Mendenhall WM, Au SK, Yau S, Mang O et al. Differentiated thyroid carcinoma in childhooh and adolescence- clinical course and role of radioiodine. Pediatr Blood Cancer 2004;42:176-83.
97. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metabol 2001;86:1447-63.
98. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer, new paradigms using recombinant human thyrotropin. Endocrine-Related Cancer 2002;9:227-47.
99. McDougall IR. The case for obtaining a diagnostic whole-body scan prior to iodine 131 treatment of differentiated thyroid cancer. Thyroid 2009;19:811-4.
100. Lau WFE, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ. Management of paediatric thyroid carcinoma:recent expeience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Int Med J 2006;36:564-77.
101. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee:Series on standard operational procedures for pre-therapeuic dosimetry I:Blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405-12.
102. Robbins RJ, Robbis AK. Clinical Review 156: Recombinant hyma thyrogen and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-8.
103. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administrated doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metabol 2007;92:3542-6.
104. Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Bucsky P et al. Procedure guideline for radioiodine therapy and 131-iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 2007;46:224-31.